.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

New use permitted: FDA approves latanoprost as first-line IOP reducer

February 1, 2003

Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.